M. Scot Roberts - 01 Jul 2022 Form 4 Insider Report for Altimmune, Inc. (ALT)

Role: Chief Scientific Officer
Signature: /s/ Richard Eisenstadt, as Attorney-in-Fact
Issuer symbol: ALT
Transactions as of: 01 Jul 2022
Net transactions value: -$365,456
Form type: 4
Filing time: 05 Jul 2022, 17:15:44 UTC
Previous filing: 30 Jun 2022
Next filing: 03 Aug 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ALT	Common Stock, par value $0.0001	Options Exercise	$10,449	+4,019	+23%	$2.60	21,719	01 Jul 2022	Direct
transaction	ALT	Common Stock, par value $0.0001	Options Exercise	$67,741	+22,963	+106%	$2.95	44,682	01 Jul 2022	Direct
transaction	ALT	Common Stock, par value $0.0001	Sale	$323,784	-26,982	-60%	$12.00	17,700	01 Jul 2022	Direct	F1
transaction	ALT	Common Stock, par value $0.0001	Options Exercise	$2,322	+787	+4.4%	$2.95	18,487	05 Jul 2022	Direct
transaction	ALT	Common Stock, par value $0.0001	Sale	$122,184	-10,182	-55%	$12.00	8,305	05 Jul 2022	Direct	F1
holding	ALT	Common Stock, par value $0.0001						15	01 Jul 2022	Shares held by spouse of Reporting Person

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ALT	Stock Options (option to buy)	Options Exercise	$0	-4,019	-31%	$0.000000	8,750	01 Jul 2022	Common Stock, par value $0.0001	4,019	$2.60	Direct	F2
transaction	ALT	Stock Options (option to buy)	Options Exercise	$0	-22,963	-60%	$0.000000	15,037	01 Jul 2022	Common Stock, par value $0.0001	22,963	$2.95	Direct	F2
transaction	ALT	Stock Options (option to buy)	Options Exercise	$0	-787	-5.2%	$0.000000	14,250	05 Jul 2022	Common Stock, par value $0.0001	787	$2.95	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2	Twenty-five percent of the shares underlying the option become vested and exercisable on the first anniversary of the Grant Date and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following the one-year anniversary of the Grant Date, in each case, generally subject to the reporting person's continued service through the applicable vesting date.

Content

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

Twenty-five percent of the shares underlying the option become vested and exercisable on the first anniversary of the Grant Date and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following the one-year anniversary of the Grant Date, in each case, generally subject to the reporting person's continued service through the applicable vesting date.